Legend Biotech initiated at outperform at Cowen on strength of Carvykti (NASDAQ:LEGN) | Seeking Alpha

Cowen has initiated Legend Biotech at outperform saying that the Carvykti (ciltacabtagene autoleucel) is poised to become the dominant CAR-T therapy for multiple myeloma.